Groupe Berkem, a leading player in plant-based chemistry, today announces its consolidated sales for the year ending December 31, 2022.
Olivier FAHY, Chairman and CEO of the Berkem Group, comments : "Despite a 2022 financial year marked by an inflationary context and persistent geopolitical tensions, the Berkem Group has managed to stay on course and continue its growth momentum, well on the way to achieving its 2024 objectives. This was made possible by strategic investments, notably in Lixol, which performed well over the period as a whole. In the fourth quarter, we also strengthened our international coverage by teaming up with the Barentz group, which now distributes our ingredients not only in North America, but also in Germany, Austria and German-speaking Switzerland. We also continue to be very active in launching new sustainable solutions aimed at accelerating our customers' ecological transition, as demonstrated by our new Ki'Leaft product. In 2023, we intend to reinforce our growth and will remain attentive to any external growth opportunities that may arise."
In October 2022, the Berkem Group announced an exclusive partnership in North America - effective November 1, 2022 - with the company Barentz, for the distribution of the Group's sustainable ingredients in the "Health, Beauty & Nutrition" market. This exclusive collaboration was extended in November 2022, with Barentz also becoming the exclusive distributor of the Berkem Group's sustainable ingredients in Germany, Austria and Switzerland. 3 In November 2022, the Group announced the launch of a new active ingredient, Ki'Leaft, on the "Health, Beauty & Nutrition" market. Ki'Leaft is a cosmos-certified 100% kiwi leaf extract of natural origin, upcycled and produced locally close to the Berkem Group's extraction plant in the Dordogne.
The Group confirms its ambition to achieve sales of at least 65 million euros by 2024, which could be increased to at least 85 million euros in the event of external growth operations. By the same date, the Group aims to achieve an Ebitda margin of around 25%.
